3-氯-N-(3-氯苯基)苯甲酰胺 | 10286-92-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯-N-(3-氯苯基)苯甲酰胺
• 英文名称: 3-chloro-N-(3-chlorophenyl)benzamide
• CAS: 10286-92-7
• 化学式: C₁₃H₉Cl₂NO
• 分子量: 266.127
• InChiKey: CNQGVYDVSJJQCU-UHFFFAOYSA-N

物化性质

• 熔点：
  112.0-113.0 °C
• 沸点：
  316.3±27.0 °C(Predicted)
• 密度：
  1.384±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  3-氯-N-(3-氯苯基)苯甲酰胺 在 氯化亚砜 、 溴 作用下， 以 二氯甲烷 、 乙酸乙酯 、 丙酮 为溶剂， 生成 2,3-bis(3-chlorophenyl)-5-N-methylimino-2H-[1,2,4]thiadiazole hydrobromide
  参考文献：
  名称：

  Synthesis and Biological Evaluation of 2,3,5-Substituted [1,2,4]Thiadiazoles as Allosteric Modulators of Adenosine Receptors

  摘要：

  A number of 2,3,5-substituted [1,2,4]thiadiazole analogues of SCH-202676 (N-(2,3-diphenyl-[1,2,4]thiadiazole-5(2H)-ylidene)methanamine, 7a) were synthesized and tested as potential allosteric modulators of adenosine receptors. All compounds were capable of displacing the binding of the radiolabeled agonist [H-3]CCPA to human A(1) adenosine receptors, whereas modest and varying effects were observed on the binding of [H-3]DPCPX, a radiolabeled antagonist for this receptor subtype. Four compounds, 7a (SCH-202676), 7k (LUF5792), 71 (LUF5794), and 8e (LUF5789), were selected for more detailed characterization. They all proved allosteric inhibitors of agonist binding, with 7k being most potent, whereas their effects on antagonist binding were more ambiguous. Subsequently, experiments were done on human adenosine A(2A) and A(3) receptors. Compounds 7a and 71 displayed peculiar displacement characteristics of both radiolabeled agonist and antagonist binding to A(2A) receptors, whereas 7a showed some activity on A(3) receptors.

  DOI：

  10.1021/jm030863d
• 作为产物：
  描述：

  Chloro-3-(trimethylstannyl)benzene 、 间氯苯异氰酸酯 在 三氯化铝 作用下， 生成 3-氯-N-(3-氯苯基)苯甲酰胺
  参考文献：
  名称：

  Kobs, Uwe; Neumann, Wilhelm P., Chemische Berichte, 1990, vol. 123, # 11, p. 2191 - 2194

  摘要：

  DOI：

文献信息

• Supported-Pd catalyzed tandem approach for N-arylbenzamides synthesis
  作者：Sheetal、Ajay Kumar Sharma、Shaifali、Dhananjay Bhattacherjee、Navneet Sharma、Kousik Giri、Pralay Das

  DOI：10.1016/j.mcat.2021.111948

  日期：2021.11

  Aryl iodides as dual arylating agent for C-terminal from oxalic acid [(CO2H)2] and N-terminal from sodium azide (NaN3) for N-aryl benzamides (Ar-CO-NH-Ar) synthesis is a rare invention which has been attempted successfully under this study. A single step tandem approach for the synthesis of N-aryl benzamides has been developed through bifunctional transformation of aryl iodides with in-situ CO from

  芳基碘作为草酸 [(CO 2 H) 2 ] 的 C 端和叠氮化钠 (NaN 3 ) 的 N端双芳基化剂，用于 N-芳基苯甲酰胺 (Ar-CO-NH-Ar) 合成是一种罕见的在这项研究中已成功尝试的发明。通过使用原位CO 从 (CO 2 H) 2和 NaN 3对芳基碘进行双功能转化，开发了一种用于合成 N-芳基苯甲酰胺的单步串联方法遵循羰基化和叠氮化两种不同的途径。发现聚苯乙烯负载的钯 (Pd@PS) 催化剂非常适合在双层小瓶 (DLV) 系统中在碱、配体和无添加剂条件下进行多米诺反应。此外，使用芳基叠氮化物进一步扩展了相同的方法，用于不对称 N-芳基苯甲酰胺 (Ar-CO-NH-Ar') 合成。此外，还进行了 DFT 研究以支持所提出的机制。
• New Insights into the Bacterial RNA Polymerase Inhibitor CBR703 as a Starting Point for Optimization as an Anti-Infective Agent
  作者：Weixing Zhu、Jörg Haupenthal、Matthias Groh、Michelle Fountain、Rolf W. Hartmann

  DOI：10.1128/aac.02600-14

  日期：2014.7

  CBR703 was reported to inhibit bacterial RNA polymerase (RNAP) and biofilm formation, considering it to be a good candidate for further optimization. While synthesized derivatives of CBR703 did not result in more-active RNAP inhibitors, we observed promising antibacterial activities. These again correlated with a significant cytotoxicity toward mammalian cells. Furthermore, we suspect the promising effects on biofilm formation to be artifacts. Consequently, this class of compounds can be considered unattractive as antibacterial agents.

  摘要 据报道，CBR703 可抑制细菌 RNA 聚合酶（RNAP）和生物膜的形成，因此被认为是进一步优化的良好候选物。虽然合成的 CBR703 衍生物没有产生活性更强的 RNAP 抑制剂，但我们观察到其具有良好的抗菌活性。这些活性再次与对哺乳动物细胞的显著细胞毒性相关联。此外，我们怀疑对生物膜形成的良好效果是伪造的。因此，这类化合物作为抗菌剂并不具有吸引力。
• Kinetics and mechanism of the aminolysis of benzoic anhydrides
  作者：Byung Choon Lee、Ji Hyun Yoon、Cheal Gyu Lee、Ikchoon Lee

  DOI：10.1002/poc.610070602

  日期：1994.6

  the latter, indicate that the reaction proceeds by a frontside SN2 attack on either one of the caronyl carbon with a strong interaction between the nucleophile (X) and the leaving group (Z). The mechanism is also supposed by the trends in the activation parameters.

  在甲醇中研究了苯环被苯环取代的苯甲酸酐的亲核取代反应。产物形成步骤与限速步骤一致，因此可以分解竞争反应途径的两个速率常数k XZ和k XZ。两个交叉相互作用常数，ρ XY和ρ XY，尤其是一个异常大的幅度后者的，表明该反应的进行通过前侧小号Ñ 2攻击的caronyl碳与亲核试剂之间的强烈的相互作用的任一个（X ）和离去组（Z）。激活参数的趋势也可以推测这种机制。
• N-Phenylbenzamide derivatives as alternative oxidase inhibitors: Synthesis, molecular properties, 1H-STD NMR, and QSAR
  作者：Paulo C.S. Costa、Mario R.O. Barsottini、Maria L.L. Vieira、Bárbara A. Pires、Joel S. Evangelista、Ana C.M. Zeri、Andrey F.Z. Nascimento、Jaqueline S. Silva、Marcelo F. Carazzolle、Gonçalo A.G. Pereira、Maurício L. Sforça、Paulo C.M.L. Miranda、Silvana A. Rocco

  DOI：10.1016/j.molstruc.2020.127903

  日期：2020.5

  DRX and 1H-NMR-STD. Single crystal X-ray diffraction showed intra- and intermolecular interactions of 3FH in solid-state and elucidated its 3D structural configuration. 1H-NMR-STD allowed us to derive protein-ligand interactions in a membrane-mimetic system and evidenced an outstanding interaction of 3FH with this enzyme. Results of both biological assays were used as input to Quantitative Structure-Activity

  摘要 在目前的工作中，制备了 117 种 N-苯基苯甲酰胺 (NPD)，并针对来自真菌病原体 Moniliophthora perniciosa 的重组 AOX 进行了评估。1H、13C NMR、FTIR 和质谱提供了 NPD 的结构信息。使用模型酵母毕赤酵母在两种不同的测定中测试文库化合物作为替代氧化酶抑制剂：细胞生长和耗氧量测定。活性最强的化合物 3FH 通过 DRX 和 1H-NMR-STD 进一步表征。单晶 X 射线衍射显示固态 3FH 的分子内和分子间相互作用，并阐明了其 3D 结构构型。1H-NMR-STD 使我们能够在膜模拟系统中推导出蛋白质-配体相互作用，并证明了 3FH 与这种酶的显着相互作用。
• Imidazo (1,2-a) Pyridines as bradykinin antagonists
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0596406A1

  公开（公告）日：1994-05-11

  A compound of the formula : wherein R1 is halogen, R2 and R3 are each hydrogen, lower alkyl, halo(lower)alkyl or acyl, R4 is aryl having suitable substituent(s), or a heterocyclic group optionally having suitable substituent(s), Q is O or N-R11, in which R11 is hydrogen or acyl, and A is lower alkylene, and pharmaceutically acceptable salts thereof, processes for their preparation and pharmaceutical compositions comprising them as an active ingredient.

  式中的化合物： 式中 R1 是卤素 R2 和 R3 分别是氢、低级烷基、卤代（低级）烷基或酰基、 R4 是具有合适取代基的芳基，或可选具有合适取代基的杂环基团、 Q 是 O 或 N-R11，其中 R11 是氢或酰基，以及 A 是低级亚烷基，及其药学上可接受的盐、制备工艺和包含它们作为活性成分的药物组合物。